Pharma & Biotech Events & Conferences
Refine Search
Biotechnology
Cellular immunotherapy specialist Fate Therapeutics soared as much as 73%, and closed up 12.45 at $2.27 yesterday, after it released early-stage data on its FT819 in lupus. 19 November 2024
Pharmaceutical
US clinical-stage biopharmaceutical company Boston Pharmaceuticals has announced positive results from a Phase II study evaluating the safety and efficacy of once-monthly efimosfermin alfa (formerly known as BOS-580), a long-acting FGF21 analogue, in participants with stage F2/F3 fibrosis due to metabolic dysfunction-associated steatohepatitis (MASH). 18 November 2024
Pharmaceutical
French drugmaker Ipsen today announced the long-term efficacy and safety of patients treated with Bylvay (odevixibat) from two Phase III open-label extension studies. 18 November 2024
Pharmaceutical
US antiviral giant Gilead Sciences on Friday unveiled two-and-a-half-year interim analysis from the ongoing Phase III ASSURE study of its Livdelzi (seladelpar). 16 November 2024
Pharmaceutical
French drugmaker Ipsen announced late-breaking data for Iqirvo (elafibranor 80mg tablets) from an interim analysis of the ongoing open-label extension of the Phase III ELATIVE study at the American Association for the Study of Liver Disease (AASLD) congress. 16 November 2024
Biotechnology
Belgian drugmaker UCB and US biotech Biogen’s Phase III PHOENYCS GO trial results signal a pivotal development for systemic lupus erythematosus (SLE) treatment, as dapirolizumab pegol met its primary endpoint and demonstrated enhanced disease control and safety at Week 48. 13 November 2024
Biotechnology
Syndax Pharmaceuticals has announced that its Phase II AUGMENT-101 trial of experimental drug revumenib achieved its primary endpoint. 13 November 2024
Pharmaceutical
Research results featured heavily in the news last week, first with Viking Therapeutics releasing promising early-stage data for its investigational medicine VK2738 at the ObesityWeek meeting. US biotech Beam Therapeutics released early-stage data on its sickle cell disease candidate BEAM-101. Also of note, Arcus Biosciences and Gilead Sciences announced promising Phase III results for their TIGIT inhibitor domvanalimab in combination with zimberelimab. Denmark’s Novo Nordisk released financial results that attracted interest. 10 November 2024
Biotechnology
Shanghai-based BioCity Biopharma has announced promising late-stage results from the Phase II 2-SUCCEED clinical trial of SC0062. 7 November 2024
Biotechnology
Results from the ARC-10 Phase III study of Arcus Biosciences and Gilead Sciences’ domvanalimab and zimberelimab combination therapy indicate a significant reduction in mortality risk for patients with certain advanced lung cancers. 7 November 2024
Biotechnology
Beam Therapeutics will detail new clinical and preclinical data on its sickle cell disease (SCD) therapies at the upcoming American Society of Hematology (ASH) meeting. 6 November 2024
Pharmaceutical
AstraZeneca has presented early results on three experimental weight-loss drugs at the ObesityWeek conference in San Antonio, showing encouraging signs for its obesity pipeline. 5 November 2024
Pharmaceutical
US neuroscience-focused biopharma Neurocrine Biosciences presented new data from more than 300 patients diagnosed with tardive dyskinesia and treated with Ingrezza (valbenazine) capsules at the 2024 Psych Congress in Boston. 5 November 2024
Pharmaceutical
Viking Therapeutics (Nasdaq: VKTX) reported promising early results for its experimental obesity pill, VK2735, with increased weight loss at higher doses. 4 November 2024
Pharmaceutical
The US subsidiary of Israel’s Teva Pharmaceutical Industries has announced new, positive data on social functioning and quality of life from the Phase III subcutaneous olanzapine extended-release injection study (SOLARIS) trial evaluating TEV-'749 in adult patients diagnosed with schizophrenia. 2 November 2024
Biotechnology
UCB has reported Phase IIa data from the TOGETHER (AH0003) study, investigating the safety, efficacy, and tolerability of bepranemab - an investigational anti-tau antibody targeting the mid-region of the tau protein - in people living with prodromal to mild Alzheimer’s disease. 1 November 2024
Biosimilars
The US unit of South Korea-based biosimilar drug developer Celltrion
has announced a late-breaking post hoc analysis of the pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC) of Zymfentra (infliximab-dyyb), during the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting. 30 October 2024
Biotechnology
US pharma major Eli Lilly has released results from two, multi-year, Phase III studies that showed patients treated with mirikizumab sustained stable, long-term remission across two types of inflammatory bowel diseases (IBD), ulcerative colitis (UC) and Crohn’s disease. 28 October 2024
Biotechnology
California’s Vera Therapeutics has released 96-week follow-up results from its ORIGIN Phase IIb trial of atacicept, targeting IgA nephropathy (IgAN). 28 October 2024
Pharmaceutical
Data presented at the 2020 annual congress of the European Society of Medical Oncology (ESMO) show long-term progression-free survival (PFS) benefit versus placebo for Lynparza (olaparib). 18 September 2020
Pharmaceutical
At the annual congress of the European Society of Medical Oncology (ESMO), taking place virtually, Johnson & Johnson’s pharma arm Janssen hopes to raise the bar with quality of life data for Erleada (apalutamide). 17 September 2020
Biotechnology
Despite a range of online resources to facilitate interactions between attendees, there clearly won’t be the same opportunities for networking at this year’s annual congress of the European Society of Medical Oncology (ESMO). 15 September 2020
Biotechnology
Swiss pharma giant Novartis on Friday presented new data on two of its already marketed multiple sclerosis (MS) drugs, Kesimpta (ofatumumab), and blockbuster hopeful Mayzent (siponimod) at MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting. 12 September 2020
Pharmaceutical
The annual congress of the European Society of Medical Oncology (ESMO) will look a lot different this time, but that does not mean the data will be any less impactful. 4 September 2020
Pharmaceutical
With weeks to go until the virtual annual congress of the European Society of Medical Oncology (ESMO), guidance on the use of next-generation sequencing (NGS) is an important topic for discussion. 24 August 2020
Biotechnology
Roche has added to the body of evidence supporting Hemlibra (emicizumab) in hemophilia A. 13 July 2020
Pharmaceutical
Gilead Sciences (Nasdaq: GILD) revealed additional data on remdesivir, its antiviral which is already a front-runner in the treatment of COVID-19, showing that the drug also significantly reduced the death rate in infected patients. 11 July 2020
Pharmaceutical
Specialty HIV company ViiV Healthcare, majority owned by GlaxoSmithKline, has presented from the HIV Prevention Trials Network (HPTN) 083 study demonstrating the superior efficacy of investigational, long-acting, injectable cabotegravir administered every two months when compared to daily oral emtricitabine/tenofovir disoproxil fumarate 200mg and 300mg (FTC/TDF) tablets for HIV prevention. 8 July 2020
Pharmaceutical
Weeks after receiving US approval for its fourth-line gastrointestinal stromal tumor (GIST) option, Deciphera Pharmaceuticals has presented new data supporting use of the therapy. 3 July 2020
Biotechnology
In a Special Report, Mircea Cubillos, Regional Commercial Strategy Leader, Haematology, Janssen EMEA, reflects on the recent ASCO and EHA congresses. And despite the unprecedented virtual format, he claims the oncology community can come away from both events feeling excited about the future. 24 June 2020
Biotechnology
Detailed data for bimekizumab show strong efficacy in psoriasis, raising the prospect that UCB’s dual IL-17 blocker could make a bigger splash in the market than had been expected. 16 June 2020
Biotechnology
Janssen has announced new long-term plaque psoriasis data for Tremfya (guselkumab), a first-in-class treatment showing consistent, high levels of skin clearance at week 100 and week 204 (four years) in adult patients with moderate to severe plaque psoriasis. 15 June 2020
Biotechnology
Apellis Pharmaceuticals has released detailed results from the Phase III PEGASUS study, which showed superiority (p 15 June 2020
Pharmaceutical
Astellas Pharma has announced data from the Phase III DOLOMITES study of roxadustat, at the 57th European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) congress, taking place online. 8 June 2020
Biotechnology
Positive Phase III results from the ILLUMINATE-A study of lumasiran, an investigational RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) – the gene encoding glycolate oxidase (GO) – in development for the treatment of primary hyperoxaluria type 1 (PH1), were presented by US RNAi specialist Alnylam Pharmaceuticals at the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) International Congress on Sunday. 8 June 2020
Biotechnology
Japan’s largest drugmaker Takeda Pharmaceutical has announced findings from two new interim analyses of data from the Phase III HELP (Hereditary Angioedema Long-term Prophylaxis) Study Open-label Extension (OLE) at the 2020 European Academy of Allergy and Clinical Immunology (EAACI) Digital Congress. 8 June 2020
Pharmaceutical
French pharma major Sanofi has set out its four-pronged plan for oncology blockbusters. 4 June 2020
Biotechnology
Pharma giant Novartis has announced full positive results from the Phase III PREVENT trial of Cosentyx (secukinumab) in axial spondyloarthritis. 4 June 2020
Biotechnology
Interleukin (IL)-17A antagonist Taltz (ixekizumab) demonstrated consistent efficacy and long-term potential to help patients with psoriatic arthritis (PsA) in new data to be presented virtually on June 5 at the European Congress of Rheumatology 2020 (EULAR). 3 June 2020
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze